+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Insulin Drugs Global Market Report 2020

  • ID: 4977355
  • Report
  • February 2020
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Actrapid
  • Eli Lilly
  • Insuman
  • Novo Nordisk
  • Ryzodeg
  • Toujeo
  • MORE
Insulin Drugs Market Global Report 2020 from the publisher provides the strategists, marketers and senior management with the critical information they need to assess the global insulin drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the insulin drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Insulin Drugs market global report from the publisher answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider insulin drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
  • The insulin drugs market section of the report gives context. It compares the insulin drugs market with other segments of the insulin drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, insulin drugs indicators comparison.
Scope
  • Markets Covered: 1) By Product Type: Basal or Long Acting Insulins; Bolus or Fast-Acting Insulins; Traditional Human Insulins; Combination Insulins; Biosimilar Insulins 2) By Application: Type II Diabetes; Type I Diabetes; Gestational Diabetes; Prediabetes
  • Companies Mentioned: Apidra; Eli Lilly; Humalog; Humulin; Insuman
  • Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time series: Five years historic and forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actrapid
  • Eli Lilly
  • Insuman
  • Novo Nordisk
  • Ryzodeg
  • Toujeo
  • MORE
1. Executive Summary

2. Insulin Drugs Market Characteristics

3. Insulin Drugs Market Size And Growth
3.1. Global Insulin Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Insulin Drugs Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Insulin Drugs Market Segmentation
4.1. Global Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Basal or Long Acting Insulins
  • Bolus or Fast-Acting Insulins
  • Traditional Human Insulins
  • Combination Insulins
  • Biosimilar Insulins
4.2. Global Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Type II Diabetes
  • Type I Diabetes
  • Gestational Diabetes
  • Prediabetes
5. Insulin Drugs Market Regional And Country Analysis
5.1. Global Insulin Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Insulin Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Insulin Drugs Market
6.1. Asia-Pacific Insulin Drugs Market Overview
6.2. Asia-Pacific Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Insulin Drugs Market
7.1. China Insulin Drugs Market Overview
7.2. China Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Insulin Drugs Market
8.1. India Insulin Drugs Market Overview
8.2. India Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Insulin Drugs Market
9.1. Japan Insulin Drugs Market Overview
9.2. Japan Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Insulin Drugs Market
10.1. Australia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Insulin Drugs Market
11.1. Indonesia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Insulin Drugs Market
12.1. South Korea Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Insulin Drugs Market
13.1. Western Europe Insulin Drugs Market Overview
13.2. Western Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Insulin Drugs Market
14.1. UK Insulin Drugs Market Overview
14.2. UK Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Insulin Drugs Market
15.1. Germany Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Insulin Drugs Market
16.3. France Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Insulin Drugs Market
17.1. Eastern Europe Insulin Drugs Market Overview
17.2. Eastern Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Insulin Drugs Market
18.1. Russia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Insulin Drugs Market
19.1. North America Insulin Drugs Market Overview
19.2. North America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Insulin Drugs Market
20.1. USA Insulin Drugs Market Overview
20.2. USA Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Insulin Drugs Market
21.1. South America Insulin Drugs Market Overview
21.2. South America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Insulin Drugs Market
22.1. Brazil Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Insulin Drugs Market
23.1. Middle East Insulin Drugs Market Overview
23.2. Middle East Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Insulin Drugs Market
24.1. Africa Insulin Drugs Market Overview
24.2. Africa Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Insulin Drugs Market Competitive Landscape And Company Profiles
25.1. Insulin Drugs Market Competitive Landscape
25.2. Insulin Drugs Market Company Profiles
25.2.1. Apidra
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Eli Lilly
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Humalog
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Humulin
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Insuman
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Insulin Drugs Market

27. Insulin Drugs Market Trends And Strategies

28. Insulin Drugs Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. The Publisher
29.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Actrapid
  • Eli Lilly
  • Insuman
  • Novo Nordisk
  • Ryzodeg
  • Toujeo
  • MORE
The insulin drugs market consists of manufacturers’ sales of insulin drugs and types of Insulin by entities (organizations, sole traders and partnerships) which are used to treat diabetes. Insulin is a medication prescribed to treat type 1 diabetes and type 2 diabetes mellitus. There are several types, preparations, and dosage amounts of insulin. Insulin is a hormone that is produced naturally in our bodies. Its main role is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy. The market covered in this report does not include non insulin drugs and other antidiabetic drugs or medicine.

The global insulin drugs market was valued at about $25.44 billion in 2019 and is expected to grow to $29.39 billion at a CAGR of 7% through 2023.

The insulin drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. The North American market is the largest market for insulin drugs and is expected to continue to be the largest market during the forecast period.

The insulin drugs market covered in this report is segmented by product type into basal or long acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, biosimilar insulins. It is also segmented by application into type II diabetes, type I diabetes, gestational diabetes, prediabetes.

Changing lifestyles are leading to a higher prevalence of diabetes. This is expected to drive the demand for diabetes drugs during the forecast period. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of diabetes. According to a study conducted in 2018, there was a high prevalence of diabetes in people with sedentary lifestyles. Additionally, people suffering from obesity are up to 80 times more likely to develop type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes, thereby likely to drive the diabetes therapies market during the forecast period.

High costs and long payback periods for investment in new diabetes drugs negatively impacted the market during the historic period. The costs for drug approval processes that include multiple phases of clinical trials and screening processes with regulatory bodies such as the US FDA are very high. According to the Tufts Center for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves was about $2.7 billion in 2017, a significant increase from $320 million in the 1990s. These high costs and uncertainty regarding return on investments for drug development limited the investments by pharmaceutical companies in the development of new diabetic drugs, thus limiting the growth of the market during the historic period.

There is an increased trend of mergers and acquisitions for the new formulations in Insulin market and the companies are investing in development of new medicines in Insulin drugs market. For example, in December 2016, researchers at Lund University Diabetes Centre in Sweden, worked on CRISPR, a genome modification tool. This resulted in turning off of one of the genes which was responsible for causing diabetes. This effectively decreased beta cell death and increased insulin production in the pancreas. Insulin maker, Novo Nordisk has developed a diabetes pill and it is expected to be launched in 2020. This pill belongs to a blockbuster class of drugs, glucagon like peptide-1 (GLP-1s) that stimulate insulin production. The new drug is expected to generate about $5 billion in annual sales.

In August 2018, Novo Nordisk acquired Ziylo which is a University of Bristol spin-out company for an undisclosed amount in the UK. Novo Nordisk has full rights to Ziylo’s glucose binding molecule platform to develop glucose responsive insulins. This development is a key strategic area for Novo Nordisk and should result in more effective insulin therapy. Ziylo is a pharmaceutical Company that has developed Biomimetic Glucose Binding Molecules (GBM) for Continuous Glucose Monitors (CGM) & Glucose Responsive Insulins (GRI).

Major players in the market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, NovoRapid/Novolog
Note: Product cover images may vary from those shown
5 of 5
  • Apidra
  • Eli Lilly
  • Humalog
  • Humulin
  • Insuman
  • Lantus
  • Levemir
  • Novo Nordisk
  • Novomix
  • NovoRapid/Novolog
  • Actrapid
  • Admelog
  • Novolin/Actrapid/Insulatard
  • Ryzodeg
  • Sanofi
  • Soliqua/Suliqua
  • Toujeo
  • Tresiba
  • Xultophy
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll